of major structures in the central reward neu-rocircuitry. Also related to this point, a third limitation is the lack of publications examining multiple regions (i.e., putative circuits) within a single study. Despite these limitations, substantial progress has been made with new targets for medications development/screening identified, such as the GLT1/EAAT2 glutamate transporter or PKC-epsilon’s modulation of mGlu5 activity. Nevertheless, the research community still has much to do in unraveling the role of glutamate-associated genes in the development of alcohol dependence, especially as it relates to pharmacogenomics and personalized pharmacologic interventions.
